Search results for "Hypopituitarism"

showing 9 items of 19 documents

Congenital hypopituitarism and multiple midline defects in a newborn with non-familial Cat Eye syndrome

2022

Abstract Background Cat eye syndrome (CES) is a rare chromosomal disease, with estimated incidence of about 1 in 100,000 live newborns. The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients, and other congenital defects may also be observed. The typical associated cytogenetic anomaly relies on an extra chromosome, derived from an inverted duplication of short arm and proximal long arm of chromosome 22, resulting in partial trisomy or tetrasomy of such regions (inv dup 22pter-22q11.2). Case presentation We report on a full-term newborn, referred to us soon after birth. Physical examination showed facial dysmorphisms, including …

Chromosome Aberrations...CholestasisHydrocortisoneCongenital hypopituitarismSupernumerary marker chromosomeChromosomes Human Pair 22Chromosome DisordersGeneral MedicineCESAneuploidyChromosome AberrationHypoglycemiaHypopituitarismColobomaEye AbnormalitieChromosome DisorderCholestasiCase reportHumansFemaleEye AbnormalitiesNeonatal hypoglycemiaItalian Journal of Pediatrics
researchProduct

Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency.

2016

OBJECTIVE: GH treatment (GHT) can lead to glucose metabolism impairment through decreased insulin sensitivity and impaired pancreatic β-cell function, which are the two key components of the pathogenesis of diabetes. Therefore, in addition to insulin sensitivity, during GHT it is very important to perform a reliable evaluation of insulin secretion. However, conflicting data exist regarding the insulin secretion in children during GHT. C-peptide provides a more reliable estimate of β-cell function than insulin, but few studies evaluated it during GHT. Our aim was to assess the usefulness of C-peptide in the evaluation of insulin secretion in GH deficiency (GHD) children. DESIGN: In 48 GHD ch…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismBiologyGlucagonHypopituitarismGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceInsulin-Secreting CellsDiabetes mellitusInternal medicineInsulin SecretionmedicineHumansInsulinC-peptide growth hormone deficiencyProspective StudiesInsulin-Like Growth Factor IChildGlucose tolerance testC-Peptidemedicine.diagnostic_testHuman Growth HormoneC-peptideInsulinFastingGlucose Tolerance TestGlucagonmedicine.diseaseHormonesGrowth hormone treatment030104 developmental biologyEndocrinologychemistryArea Under CurveCase-Control StudiesChild PreschoolFemaleInsulin Resistance
researchProduct

Growth hormone potentiates thyroid hormone effects on post-exercise phosphocreatine recovery in skeletal muscle.

2012

International audience; OBJECTIVE: The aim of the study was to determine the respective impact of thyroxine and growth hormone on in vivo skeletal mitochondrial function assessed via post exercise phosphocreatine recovery. DESIGN: The hind leg muscles of 32 hypophysectomized rats were investigated using (31)P nuclear magnetic resonance spectroscopy at rest and during the recovery period following a non tetanic stimulation of the sciatic nerve. Each rat was supplemented with hydrocortisone and was randomly assigned to one of the 4 groups: the group Hx was maintained in hypopituitarism., the group HxT was treated with 1 μg/100g/day of thyroxine (T4), the group HxG with 0.2 IU/kg/day of recomb…

MalePhosphocreatineThyroid hormonesEndocrinology Diabetes and MetabolismMESH: Random AllocationThyroid GlandSkeletal muscleHypopituitarismMESH: Physical Conditioning AnimalMESH: Drug SynergismNuclear magnetic resonancechemistry.chemical_compoundRandom Allocation0302 clinical medicineEndocrinologyMESH: Human Growth HormoneMESH: AnimalsMESH : Muscle Skeletal0303 health sciencesMESH: Muscle Skeletal[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingMESH : RatsHuman Growth HormoneThyroidDrug Synergismmedicine.anatomical_structuremedicine.drugmedicine.medical_specialtyMESH : Drug SynergismMESH: RatsMESH : MaleSomatotropin030209 endocrinology & metabolismMESH: PhosphocreatinePhosphocreatineMESH : Random Allocation03 medical and health sciencesIn vivoInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyPhysical Conditioning AnimalMESH : Thyroxinemedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingAnimalsHumansMESH : PhosphocreatineMESH : Human Growth HormoneMitochondrionMESH : Physical Conditioning AnimalMuscle Skeletal030304 developmental biologyHydrocortisoneMESH: HumansMESH : HumansSkeletal muscleMESH : Thyroid GlandMESH: Thyroxinemedicine.diseaseMESH: MaleMESH: Thyroid GlandRatsThyroxineEndocrinologychemistryRatMESH : AnimalsTetanic stimulation[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHormoneGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury …

2019

Background.Xenon is a noble gas with neuroprotective properties. We previously showed that xenon improves short and long-term outcomes in young adult mice after controlled cortical impact (CCI). This is a follow-up study investigating xenon’s effect on very long-term outcome and survival. Methods.C57BL/6N (n=72) young adult male mice received single CCI or sham surgery and were treated with either xenon (75%Xe:25%O2) or control gas (75% N2:25%O2). The outcomes used were: 1) 24-hour lesion volume and neurological outcome score; 2)contextual fear-conditioning at 2 weeks and 20 months; 3) corpus callosum white matter quantification; 4) immunohistological assessment of neuroinflammation and neu…

MaleXenonhippocampusnerve degenerationCorpus callosumBUPRENORPHINEneuroinflammationMice0302 clinical medicineCognition030202 anesthesiologyAnesthesiologyBrain Injuries TraumaticMedicineEPIDEMIOLOGYYoung adultmemory disordersNeuronstraumatic brain injurySham surgeryBrain3. Good healthD-ASPARTATE RECEPTORmedicine.anatomical_structureNeuroprotective AgentsAnesthesianeuroprotectionmedicine.symptomLife Sciences & BiomedicineTraumatic brain injuryHYPOPITUITARISMNeuroprotectionWhite matter03 medical and health sciencesANALGESIAINHALED XENONAnimalsgeneral anaesthesiaSurvival analysisHYPOTHERMIAInflammationScience & Technologybusiness.industry1103 Clinical SciencesHypothermiamedicine.diseaseCOMPETITIVE-INHIBITIONSurvival AnalysisMice Inbred C57BLPATHOLOGYDisease Models AnimalAnesthesiology and Pain MedicineChronic DiseasebusinessCognition Disorders030217 neurology & neurosurgeryWHITE-MATTER DAMAGEFollow-Up StudiesBritish journal of anaesthesia
researchProduct

MRI findings and genotype analysis in patients with childhood onset growth hormone deficiency--correlation with severity of hypopituitarism.

2007

Aim: To evaluate the relationship between pituitary size, PIT1 and PROP1 genotype, and the severity of childhood onset growth hormone deficiency (coGHD). Patients: Forty-four patients with coGHD (34 M; 9.7 ± 4.1 years): severe isolated (SI) GHD (n = 14); partial isolated (PI) GHD (n = 13); multiple pituitary hormone deficiencies (MPHD) (n=17). Results: Pituitary abnormalities were found in 7/14 patients with SIGHD (50%), 16/17 patients with MPHD (94.1%), and no patient with PIGHD. Mean pituitary height (PHT SDS) was significantly lower in MPHD than in SIGHD and PIGHD. Pituitary height SDS and pituitary volume (PV) SDS correlated with IGF-I SDS and stimulated GH peaks in the SIGHD and MPHD g…

Malemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismGenotype AnalysisHypopituitarismHypopituitarismGrowth hormone deficiencyCorrelationEndocrinologyInternal medicineAge Determination by SkeletonGenotypemedicineHumansIn patientAge of OnsetChildDwarfism PituitaryRetrospective StudiesHomeodomain Proteinsbusiness.industrymedicine.diseaseMagnetic Resonance ImagingBody HeightEndocrinologyChild PreschoolPituitary GlandPediatrics Perinatology and Child HealthPituitary hormonesDisease ProgressionFemalebusinessTranscription Factor Pit-1Mri findingsJournal of pediatric endocrinologymetabolism : JPEM
researchProduct

Late-onset Sheehan's syndrome presenting with rhabdomyolysis and hyponatremia: a case report.

2013

Abstract Introduction Hyponatremia associated with rhabdomyolysis is a rare event and a correct diagnostic approach is required to rule out this or other diseases as a primary cause and to avoid other complications resulting from a lack of appropriate treatment. Case presentation A 64-year-old Caucasian woman presented to our facility with worsening fatigue, slurred speech, nausea and vomiting, and high serum levels of creatine kinase and myoglobin together with hyponatremia. Normal arterial blood gas analysis results, normal serum potassium levels, increased urine sodium levels, urine specific gravity of >1003N/m3 and low urine volume suggested an endocrine etiology. Her low cortisol an…

Medicine(all)Late-onset Sheehan's syndrome hypopituitarism hyponatremia rhabdomyolysisPediatricsmedicine.medical_specialtyPituitary disorderbusiness.industryLate onsetCase ReportGeneral MedicineHypopituitarismmedicine.diseaseUrine sodiummedicineVomitingSheehan's syndromemedicine.symptomHyponatremiabusinessRhabdomyolysisJournal of medical case reports
researchProduct

Use of a clinicoradiological score to determine the presurgical diagnosis of autoimmune hypophysitis in a teenage girl.

2013

The distinction between autoimmune hypophysitis and other non–hormone secreting pituitary masses is often difficult to determine with certainty without pituitary biopsy and pathological examination. To aid in this distinction, the authors recently published a clinicoradiological scoring system, which they used in the case of a 15-year-old girl presented here. The patient presented with headache, visual field defects, polydipsia, and polyuria, and she was found to have secondary hypogonadism and hypoadrenalism. Magnetic resonance imaging showed a pituitary mass of approximately 2 cm in diameter. Application of the clinicoradiological parameters gave a score of −6, which favored a diagnosis o…

Pituitary glandmedicine.medical_specialtyPathologyAdenomaAdolescentHypophysitisPrednisoloneAnti-Inflammatory AgentsHypopituitarismHypopituitarismAutoimmune DiseasesPolyuriaHypoadrenalismmedicineHumansbusiness.industryHeadacheGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingRadiographyPituitary Hormonesmedicine.anatomical_structureTreatment OutcomePituitary GlandAutoimmune hypophysitisPrednisoloneFemaleRadiologymedicine.symptombusinessmedicine.drugJournal of neurosurgery. Pediatrics
researchProduct

Craniopharyngiomas in Children - Experience of Consecutive 152 Operated Cases

2020

Context Craniopharyngiomas (CPH) are benign tumors, rarely encountered in children, representing 5-6% of all intracranial tumors. Objective This study aimed to analyze the surgical management and quality of life in a series of CPH pediatric cases. Design This was a multicenter study performed over a 25-year period (1994 - 2019) in Bucharest. Subjects and methods 152 children (0-17 years old) were treated for CPH. Preoperative manifestations were intracranial hypertension, endocrine dysfunction, visual impairment, ataxia, intellectual performance decrease. Results Considering all surgical approaches used, we advocate for pterional approach to best fit in CPH. We achieved gross-total removal …

medicine.medical_specialtyAtaxiaEndocrine and Autonomic Systemsbusiness.industryEndocrinology Diabetes and MetabolismGlasgow Outcome ScaleVisual impairmentContext (language use)Hypopituitarismmedicine.diseaseSurgeryHydrocephalus03 medical and health sciences0302 clinical medicineEndocrinologyQuality of life030220 oncology & carcinogenesisDiabetes insipidusmedicineCase Seriesmedicine.symptombusiness030217 neurology & neurosurgeryActa Endocrinologica (Bucharest)
researchProduct

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study

2019

Background:Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the effects of 12-month DR-HC treatment on the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, in patients with secondary adrenal insufficiency (SAI).Methods:A total of 45 patients with hypopituitarism, 22 with hypogonadism, hypothyroidism, ACTH, and GH deficiencies, and 23 with hypogonadism, hypothyroidism, and ACTH deficiency, on replacement therapy for all the pituitar…

medicine.medical_specialtySecondary adrenal insufficiencyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypopituitarismHepatic steatosilcsh:Diseases of the endocrine glands. Clinical endocrinologyHypopituitarismSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenal insufficiencyIn patientHydrocortisoneOriginal Researchlcsh:RC648-665business.industryhepatic steatosismedicine.diseaseInsulin sensitivityEndocrinology030220 oncology & carcinogenesisDual-release hydrocortisoneSteatosisLife studybusinessGlucocorticoidmedicine.drugSecondary adrenal insufficiency
researchProduct